Review of quetiapine and its clinical applications in schizophrenia

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 4, 2000, Pages 783-801

  Kasper, Siegfried ^a,b,c   Miiller Spahn, Franz ^a,b,c  

^a UNIVERSITY OF VIENNA   (Austria)

^b Department of Psychiatry ^*  (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Atypical antipsychotic; Clinical efficacy; EPS; Quetiapine (seroquel ); Tolerability

Indexed keywords

DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; QUETIAPINE;

CLINICAL TRIAL; HUMAN; PSYCHOLOGY; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; DIBENZOTHIAZEPINES; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0034189369     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.4.783     Document Type: Article

References (87)

1. JABLENSKY A: Schizophrenia: the epidemiological horizon. In: Schizophrenia. Hirsch SR, Weinberger DR (Eds.), Blackwell, Oxford, UK (1995):206-252.
2. KESSLER RC, MCGONAGLE KA, ZHAO S et al- Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch. Gen. Psychiatry (1994) 51:8-19-
3. GUNDERSON JG, MOSHER LR: The cost of schizophrenia. Am.J. Psychiatry (1975) 132:901-906.
4. CALDWELL CB, GOTTESMAN II: Schizophrenics kill themselves too: a review of risk factors for suicide. Schizopbr. Bull. (1990) 16:571-589.
5. MÜIXER-SPAHN F, EICH PH, HOCK C: The psychobiology of the acute schizophrenic episode. Int. J. Clin. Psychopbannacol. (1996) IKSuppl. 2):19-28.
6. CREESE I, BURT DR, SNYDER SH: Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrcnic drugs. Science (1976) 192:481-483.
7. COLE JO, GOLDBERG SC, KLERMAN GL: Phenothiazine treatment in acute schizophrenia. Arch. Gen. Psychiatry (1964) 10:246-261.
8. JIBSON MD AND TANDON R: The negative symptoms of schizophrenia. Directions Psychiatry (1995) 15:1-7.
9. BILDER RM: Neurocognitive impairment in schizophrenia and how it affects treatment options. Can.]. Psychiatry (1997) 42:255-264.
10. HOGE SK, APPELBAUM PS, LAWLOR T et al.: A prospective multiccnter study of patients' refusal of antipsychotic medication. Arch. Gen. Psychiatry (1990) 47:949-956.
11. GHADIRIAN AM, CHOUINARD G, ANNABLE L: Sexual dysfunction and plasma prolactin levels in ncuroleptic - treated schizophrenic outpatients. Nerv. Ment. Dis. (1982) 170:463-467.
12. ABI-DARGHAM A, LARUELLE M, AGHAJANIAN G, CHARNEY D, KRYSTAL J: The role of scrotonin in the pathophysiology and treatment of schizophrenia. Neiiropsychlatry Clin. Neumsci. (1997) 9:1-17.
13. KAPUR S, REMINGTON G: Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry (.199S) 153:466-476.
14. AMSLER HA, TEERENHOVI L, BARTH E, HARJULA K, VUOPIO P: Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic. Ada. Psychiatr. Scand. (1977) 56:241-248.
15. KANEJ, HONIGFELD G, SINGER J, MELTZER H AND THE CLOZARIL COLLABORATIVE STUDY GROUP: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry (1988) 45:789-796. Seminal trial providing conclusive evidence for dozapine's unique effects in treatment-resistant patients.
16. JIBSON MD, TANDON R: New atypical antipsychotic medications./ Psychiatr. Res. (1998) 32:215-228.
17. Collaborative Working Group on Clinical Trial Evaluations. Evaluating the effects of antipsychotics on cognition in schizophrenia. / Clin. Psychiatry (1998) 59(Suppl. 12):35-40.
18. OWENS DG: Extrapyramidal side effects and tolerability of risperidonc: a review./ Clin. Psychiatry (1994) 55(Suppl.):29-35.
19. ELI LILLY & CO.: Olanzapine US prescribing information. (1999).
20. ARVANITIS LA, MILLER BG: Multiple fixed doses of 'Scroqucl' (quetiaplne) in patients with acute exacerbation of schizophrenia: a comparison with halopcridol and placebo, ne Seroqtiel Trial 13 Study Group. Biol. Psychiatry (1997) 42:233-246. One of the pivotal trials showing quetiapine efficacy with no EPS across the dose range.
21. KLEINBERG DL, DAVIS JM, DE COSTER R, VAN BAELEN B, BRECHER M: Prolactin levels and adverse events hi patients treated with risperidone. J Clin. Psychopbarmacol. (1999) 19:57-61.
22. BEASLEY CM, HAMILTON SH, CRAWFORD AM et al.: Olanzapine versus halopcridob acute phase results of the international double blind olanzapine trial. Enr. Nettropsychophamiacol. (1997) 7:125-137.
23. SMALL JG, HIRSCH SR, ARVANITIS LA, MILLER BG, LINK CG: Quetiapine in patients with schizophrenia. A highand low-dose double-blind comparison with placebo. Seroquel Study Group. Arch. Gen. Psychiatry (1997) 54:549-557.
24. SALLERF, SALAMA AI: Seroquel; biochemical profile of a potential atypical antipsychotic. Psychopbarmacology (1993) 112:285-292.
25. GOLDSTEIN J, ARVANITIS L: ICI 204, 636 (Seroquel): a dibenzotniazepinc atypical antipsychotic. Review of preclinical pharmacology and highlights of Phase n clinical trials. CNS Drug Reviews (1995) 1:50-73-
26. GOLDSTEIN JM: Preclinical profile of Seroquel (quetiapine): an atypical antipsychotic with clozapine-likc pharmacology. In: Schizophrenia: Breaking Down the Barriers. Holliday SG, Ancill RJ, MacEwan GW (Eds.), John Wiley & Sons Ltd. (1996):177-236.
27. MIGLER BM, WARAWA EJ, MALICK JB: Seroquel: behavioural effects in conventional and novel tests for atypical antipsychotic drug. Psychophannacology(.\y)y) 122:299-307.
28. ELLENBROEK BA, LUBBERS LJ, COOLS AR: Activity of 'Scroqucl' (ICI 204,636) in animal models for atypical properties of antipsychotics: a comparison with clozapine. Netiropsycbopbarmacology(.l996) 15:406-416. An overview of quetiapine's preclinical profile, noting certain similarities with clozapine.
29. SAMS-DODD F: Phencyclidlne in the social interaction test: an animal model of schizophrenia with face and predictive validity. Rev. Neurosci. (1999) 10:59-90.
30. KASPER S, TAUSCHER J, KUFFERLE B et al.-. Dopamineand serotonin-receptors in schizophrenia: results of Imaging-studies and implications for pharmacology in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. (1999) 249(Suppl. 4):83-89.
31. KUFFERLE B, TAUSCHER J, ASENBAUM S et al.: IBZM SPECT imaging of striatal dopamlne-2 receptors hi psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and halopcridoL Psycbopbarmacology (1997) 133:323-328.
32. GOLDSTEIN JM, LITW1N LC, SUTTON EB, MALICK JB: Seroquel: electrophysiological profile of a potential atypical antipsychotic. Psycbopbarmacology (1993) 112:293-298.
33. ROBERTSON GS, MATSUMURA H, FIBIGER HC: Induction patterns of Fos-like immunoreactivity in the forcbrain as predictors of atypical antipsychotic activity. J. Pbarmacol. Exp. Tber. (1994) 271:1058-1066.
34. VAHID-ANSAR F, NAKABEPPU Y, ROBERTSON GS: Contrasting effects of chronic clozapine, Seroquel(TM) (ICI 204,636) and haloperidol administration of deltaFosB-like immunoreactivity in the rodent forebrain. Eur.J. Neurosci. (1996) 8:927-936.
35. VAHID-ANSARI F, ROBERTSON GS: 7-OH-DPAT differentially reverses clozapine- and haloperidol-induced increases in Fos-like imfnunoreactivity in the rodent forebrain. Eur.J. Neurosci. (1996) 8:2605-2611.
36. CAREY GJ, BERGMAN J: Discriminative-stimulus effects of clozapine in squirrel monkeys: comparison with conventional and novel antipsychotic drugs. Psycbopbarmacolpgy(.l997) 132:261-269.
37. WONG JYW, EWING BJ, THYRUM PT, YEH C: Multipledose pharmacokinctics of 'Scroqucl' (quetiapine) hi elderly psychotic patients. Schizophrenia Res. (1997) 24:199.
38. WONG JYW, EWING BJ, THYRUM PT, YEH C: Multipledose pharmacokinctics of 'Scroqucl' (quetiapine) in schizophrenic men and women. Schizophrenia Res. (1997) 24:200.
39. WONG JYW, EWING BJ, THYRUM PT, YEH C: Pharmacokinctics of 'Seroquel' (quetiapine) in hepatic and renal insufficiency. Schizophrenia Res. (1997) 24:200. Abstract.
40. BORISON RL, ARVANITIS LA, MILLER BG, FOR THE US SEROQUEL STUDY GROUP: ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicentcr, placebo-controlled trial in patients with schizophrenia./ Clin. Psychopharmacol. (1996) 16:158-169.
41. PEUSKENSJ, LINK CG: A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta. Psychiatr. Scand. (1997) 96:265-273.
42. COPOLOV DL, LINK CGG, KOWALCYK B: A muhicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia. Psychol. Med. (2000) 30:95-106.
43. BEASLEY CM, SANGER T, SATTERLEE W étal.: Olanzapine versus placebo: results of a double-blind, fixed dose olanzapine trial. Psycbopbarmacology (1996) 124:159-167.
44. TOLLEFSON GD, BEASLEY CM, TAMURA RN et al.: Blind, controlled, long term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or halopcridoL Am.]. Psycbiatry(l997) 154:1248-1254.
45. TRAN PV, HAMILTON SH, KUNTZ AJ et al.: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders./ Clin. Psychopharmacol. (1997) 17:407-418.
46. MARDER SR, MEIBACH RC: Risperidone in the treatment of schizophrenia. Am.]. Psychiatry (1994) 151:825-835.
47. CHOUINARD G, JONES B, REMINGTON G et al.: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. / Clin. Psycbopbarmacol. (1993) 13:25-0.
48. PEUSKENS J: Risperidone In the treatment of patients with chronic schizophrenia: a multi-national, multicentre, double-blind, parallel-group study versus halopcridoL Risperidone Study Group. Br.J. Psychiatry (1995) l66:712-726;727-733 (Dtecussion).
49. BLIN O, AZORIN JM, BOUHOURS P: Antipsychotic and anxiolytic properties of risperidone, haloperidol and methotrimeprazine in schizophrenic patients./ Clin. Psycbopbarmacol. (1996) 16:38-44.
50. MÜLLEN J, REINSTEIN M, BARI M, GINSBERG L, SANDLER N: Quetiapine and risperidone in outpatients with psychotic disorders: results of the QUEST trial. Eur. Neuropsychopbarmacol. (1999) 9(Suppl. 5):S267. Demonstrates quetiapine's superior risk-benefit profile.
51. BEASLEY CM, TOLLEFSON G, TRAN P et al.: Olanzapine versus placebo and halopcridoL Acute phase results of the North American double-blind olanzapine trial. Keuropsycbophannacology (1996) 14:111-123.
52. EMSLEY RA, RANIWALLA J, BAILEY PJ, JONES AM: A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int. Clin. Psychopharmacol .(2000) 15(3):121-131. Innovatively designed trial in partial responders, showing superior response to quetiapine 600 mg/day.
53. RAK I, RANIWALLA J: Maintenance of long-term efficacy with SeroqueL Schizophrenia Res. (2000) 4l(l):B74.
54. DRAKE RE, EHRLICH J: Suicide attempts associated with akathisia. Am.J. Psychiatry (1985) 142:499-501.
55. BELLUS SB, STEWART D, KOST PP: Clozapine in aggression. Psychiatr. Serv. (1995) 46(2):187.
56. SETH A, COHEN MD, UNDERWOOD T et al.-. The use of clozapine in a mentally retarded and aggressive population./ Clin. Psychiatry (1994) 55:440-444.
57. HELLEWELL J, CANTILLON M, MCKELLAR M et al.: 'Seroquel': efficacy in aggression, hostility and low mood of schizophrenia. Int. J. Neuropsycbopharmacol. (1999) 2 (Suppl. 1): S112.
58. SCHNEIDER L, YEUNG P, SWEITZER D, ARVANITIS L: Effects of Seroquel (quetiapine) on reducing hostility and psychosis in patients with Alzhcimer's disease. American Psychiatric Association Annual Meeting. Washington DC, USA (1999).
59. PURDON S, MALLA A, LABELLE A, LITT W: Ncuropsychological change in schizophrenia after 6 months of double-blind treatment with quetiapinc or haloperidoL Schizophrenia Res. (2000) 41(1):B82.
60. SAYKIN JA, GUR RC, GUR RE et al.: NeuropsychologJcal function in schizophrenia: selective impairment in memory and learning. Arch. Gen. Psychiatry (1991) 48:618-624.
61. SPOHN HE, STRAUSS ME: Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia./ Abnorm. Psychol. (1989) 98:367-380.
62. SAX KW, STRAKOWSKI SM, KECK PE Jr: Attentional improvement following quetiapine fumarate treatment in schizophrenia. Schizophrenia Res. (1998) 33:151-155.
63. FLEMING K, KALALI A, YEH C, VARGO DL, THYRUM PT, POTKIN SG: The neurocognitive effects of quetiapine (Seroquel, ICI 204636). Schizophrenia Res. (1997) 24:197.
64. VELLIGAN DI, NEWCOMER J, PULTZ J et al.: Changes in cognitive functioning with quetiapine fumarate versus haloperidoL American College of Neuropsycbopharmacology Annual Meeting. Acapulco, Mexico (1999). Significant effects on cognitive function observed after treatment with quetiapine 600 mg/day.
65. MCCONVILLE B, ARVANITIS L, THYRUM P, JONES AM: Quetiapine in adolescents with psychotic disorders. World Psychiatric Association Annual Meeting. Hamburg, Germany (1999).
66. MCMANUS DQ, ARVANITIS LA, KOWALCYK BB FOR THE SEROQUEL TRIAL 48 STUDY GROUP: Quetiapine, a novel antipsychotic: experience hi elderly patients with psychotic disorders.J. Clin. Psychiatry (1999) 60:292-298. Demonstrated quetiapine to be efficacious and well tolerated in this particularly vulnerable group of patients.
67. TARIOT P, SALZMAN C, YEUNG P, PULTZ J, GOLDSTEIN J, RANIWALLA J: Clinical improvement and tolerability is maintained long term in elderly patients with psychotic disorders treated with Seroquel (quetiapine). American Psychiatric Association Annual Meeting. Washington DC, USA (1999).
68. JUNCOS J, YEUNG P, SWEITZER D, ARVANITIS L, NEMEROFF C: Seroquel (quetiapine) improves psychotic symptoms associated with Parkinson's discase. American Psychiatric Association Annual Meeting, Washington DC, USA (1999).
69. PARSA MA, GREENWAY HM, BASTANI B: Treatment of psychosis in patients with I'arkinson's disease and dementia (Lewy body disease variant) with quctlapine. World Psychiatric Association Annual Meeting. Hamburg, Germany (1999).
70. BARNES TRE, BRAUDE WM: Akathisia variants and tardive dyskinesia. Arch. Gen. Psychiatry (1985) 42:874-878.
71. BURKE RE, KANG UJ, JANKOVIC J et al,: Tardive dyskinesia: an analysis of clinical features and response to open therapeutic trials. Mov. Disord. (1989) 4:157-175.
72. KLAWANS HI, GOETZ CG, PERLIK S: Tardive dyskinesia, review and update. Am.J.Psycbiatry(.1980) 137:900-908.
73. GLAZER WM, MORGENSTERN H, PULTZ JA, YEUNG PP, RAK IW: Incidence of persistent tardive dyskinesia is lower with quetiapine treatment than with typical antipsychotics in patients with schizophrenia and schizoaffective disorder. Schizophrenia Res. (2000) 4l(l):B45.
74. JESTE DV, CALIGURLI MP, PAULSEN JS et al.: Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch. Gen. Psychiatry (1995) 52:756-705.
75. JESTE DV, GLAZER WM, MORGENSTERN H, PULTZ JA, YEUNG PP: Rarity of persistent tardive dyskinesia with quetiapine treatment of psychotic disorders in the elderly. AnnualMeeting of the American College ofNettropsychopharmacology. 4capulco, Mexico (1999). Quetiapine's unique EPS profile translates into a very low propensity to induce tardive dyskinesia in elderly patients.
76. PEUSKENS J: Prolactin elevation and sexual dysfunction. Clear Perspectives (1998) l(3):17-27.
77. GOLDSTEIN JM, ARVANITIS LA, CANTILLON M: Low incidence of reproductive/hormonal side effects with 'Seroqucl' (quetiapine fumarate) is supported by its lack of elevation of plasma prolactin concentrations. 36th AnnualMeeting of the American College ofKeuropsychology. Waikoloa, Hawaii, USA (1997). Demonstrates quetiapine's benign profile with regards to prolactin effects and subsequent impact on sexual function.
78. MEATS P: Quetiapine ('Seroquel'); an effective and well-tolerated atypical antipsychotic. Int. J. Psychiatry Clin. Pract. (1997) 1:231-239.
79. GUNASEKARA NS, SPENCER CM: Quetiapine. a review of its use in schizophrenia. CNS Drugs (1998) 9:325-340.
80. ATKINSON GA, HELLEWELL JSE, RANIWALLA J. Seroquel (quetiapine) in the treatment of schizophrenia overview of efficacy data in six Phase n/III clinical trials. Eur. Neuropsycbopbarmacol. (1997) 7(Suppl. 2):S224.
81. ALLISON DB, MENTORE JL, HEO M et al.: Antipsychoticinduced weight gain: a comprehensive research synthesis. Am.]. Psychiatry (1999) 156:1686-1696.
82. JONES AM, RAK IW, RANIWALLA J, PHUNG D, MELVIN K: Weight changes in patients treated with 'Seroquel' (quetiapinc). Schizophrenia Res. (2000) 41 (1):B83. Demonstrates quetiapine to have minimal effects on weight during long-term treatment.
83. BRECHER M, GELLER W: Weight gain with risperidone / Clin. Psycbopharmacol. (1997) 17:435-36.
84. NEMEROFF CD: Dosing the antipsychotic medication olanzapine./ Clin. Psychiatry(\y)7) 58(Suppl. 10):45-49.
85. KALALI A: Patient satisfaction with and acceptibility of, atypical antipsychotics. Curr. Med. Kes. Opin. (1999) 15:135-137.
86. HELLEWELL JSE, KALALI AH, LANGHAM SJ, MCKELLARJ, AWAD AG: Patient satisfaction and acceptability of long-term treatment with quetiapine. Int.]. Psych. Clin. Pract. (1999) 3:105-113. Demonstrates quetiapine's high acceptability to patients during long-term treatment.
87. GORMAN AP, RAK IW, WESTHEAD EK, JONES AM: The long term effect of quetiapine (Seroquel) on weight in patients with schizophrenia. Int. J. Psych. Clin. Pract. (2000) (Submitted).